CVS Corp (CVS) 101.90 $CVS Wal-Mart To Benefit From

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
CVS Corp (CVS) 101.90 $CVS

Wal-Mart To Benefit From Currency Risk Environment
Morgan Myrmo - at Seeking Alpha - Sat Mar 07, 8:01AM CST

TGT: 77.21 (-0.99), WMT: 82.59 (-0.98), CVS: 101.90 (-1.46), COST: 149.54 (-1.63)

Target: What Slowing Dividend Growth Means For Investors
Eli Inkrot - at Seeking Alpha - Fri Mar 06, 2:20PM CST

JPM: 60.89 (-1.11), USB: 44.67 (+0.09), TGT: 77.21 (-0.99), CVS: 101.90 (-1.46), WFC: 54.59 (-0.25)

Here’s a Reason Rite Aid (RAD) Stock Fell Today
at The Street - Thu Mar 05, 3:05PM CST
Rite Aid (RAD) stock was lower today after the company issued its same-store-sales results for February, which increased year-over-year but slowed down from January.
CVS: 101.90 (-1.46), RAD: 7.65 (-0.03)

CVS: Will Strong Dividend Growth Provide Solid Returns?
Eli Inkrot - at Seeking Alpha - Thu Mar 05, 11:14AM CST

CVS: 101.90 (-1.46)

CVS Caremark declares $0.35 dividend
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 9:48AM CST

CVS: 101.90 (-1.46)

CVS Health Wins Over Analysts As Significant Growth Expected In The Next 5 Years
Equity Watch - at Seeking Alpha - Wed Mar 04, 8:17AM CST

GILD: 101.81 (-1.61), CVS: 101.90 (-1.46)

Cardinal Health Set to Buy Cordis, Shares Hit 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 10:26AM CST
Cardinal Health Inc. (CAH) hit a 52-week high of $90.49 on Mar 2, 2015, after the company announced plans to acquire Cordis, a unit of Johnson & Johnson (JNJ).
JNJ: 100.11 (-2.41), CAH: 87.01 (-1.94), CVS: 101.90 (-1.46), HSIC: 137.84 (-2.78)

Horizon Pharma Soars On Q4 Beat, Guidance Raise
at Investor's Business Daily - Fri Feb 27, 10:48AM CST
Specialty drugmaker Horizon Pharma (HZNP) beat analysts' Q4 expectations and raised its 2015 guidance Friday, sending its stock up 10% to a new high. Horizon's revenue in the quarter more than tripled to $103.8 million, about $8 million above...
ESRX: 82.27 (-2.01), AZN: 66.27 (-1.91), HZNP: 21.91 (+1.07), CVS: 101.90 (-1.46)

Catamaran EPS Tops, But Stock Falls On Weak Guidance
at Investor's Business Daily - Thu Feb 26, 10:59AM CST
Catamaran (CTRX) surpassed fourth-quarter earnings and sales estimates on Thursday, but shares sank on its weak full-year EPS outlook. The provider of pharmacy benefit management services saw adjusted earnings climb 19.6% to 67 cents a share in Q4,...
ESRX: 82.27 (-2.01), CTRX: 48.57 (-1.03), BRLI: 32.97 (-0.74), AAC: 29.30 (-2.80), CVS: 101.90 (-1.46), RAD: 7.65 (-0.03)

Impeccable Quality But There Are No Bargains Today In The S&P 500 Consumer Staples Sector: Part 8
Chuck Carnevale - at Seeking Alpha - Wed Feb 25, 11:00AM CST

WFM: 55.66 (-0.49), KO: 41.52 (-0.88), DPS: 78.35 (-0.55), PM: 80.05 (-1.66), AVP: 8.90 (-0.15), MKC: 73.45 (-1.28), CAG: 34.26 (-0.60), CVS: 101.90 (-1.46), COST: 149.54 (-1.63), PG: 82.66 (-1.97), GIS: 52.13 (-1.15), BF.B: 88.76 (-2.03)

Billions on the Line in the Next Drug Pricing War
Keith Speights, The Motley Fool - Motley Fool - Tue Feb 24, 7:02AM CST
Source: Gilead Sciences  One win whets the appetite for another. That certainly seems to be the case for the nation's two largest pharmacy benefits managers, Express Scripts and CVS Health . After scoring a victory in bringing hepatitis C...
ESRX: 82.27 (-2.01), GILD: 101.81 (-1.61), CVS: 101.90 (-1.46), REGN: 422.13 (-6.82)

$20 Billion Market: What’s the Best Stock to Buy?
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Fri Feb 20, 7:01AM CST
Modern drugs, known as "biologics," are harder to develop and harder to replicate than the conventional small molecule medications we all grew up with. As a result, competitors have to work harder to develop generic approximations of them, known as...
ESRX: 82.27 (-2.01), MRK: 56.84 (-1.14), PFE: 33.97 (-0.50), MYL: 55.44 (-1.25), CVS: 101.90 (-1.46), AMGN: 154.88 (-4.72), TEVA: 56.40 (-0.11), ABBV: 55.64 (-1.22), HSP: 87.90 (+0.05), NVS: 97.46 (-1.49)

Oil Price Collapse Gives Patient Investors a Convenient Excuse to Buy
Rich Duprey, The Motley Fool - Motley Fool - Thu Feb 19, 8:02AM CST
It feels so 2008 with gas prices below $2.00 a gallon, and it creates a convenient time for investors to profit. Photo: Flickr via Minale Tattersfield. You have to go back to the depths of the Great Recession to find gasoline prices as...
MPC: 98.49 (-3.26), MCD: 97.13 (-1.98), CVS: 101.90 (-1.46), BKW: 35.50 (-1.16)

At Least Highly Rated Retailers Click With Consumers
at Investor's Business Daily - Wed Feb 18, 7:02AM CST
When it came to customer satisfaction ratings, the nation's retailers capped 2014 on a sour note. In the last quarter of 2014, customer satisfaction was down for the first time in four years, according to a report that the American Customer...
WFM: 55.66 (-0.49), AMZN: 380.09 (-7.74), HD: 114.45 (-1.46), M: 62.98 (-0.21), WMT: 82.59 (-0.98), FDO: 78.80 (+0.10), RAD: 7.65 (-0.03), NFLX: 454.12 (-13.53), LB: 90.09 (-1.14), DLTR: 79.61 (+0.18), WBA: 82.35 (-0.85), TGT: 77.21 (-0.99), CVS: 101.90 (-1.46), COST: 149.54 (-1.63), JWN: 80.86 (+0.21), DG: 71.32 (-0.39), LOW: 73.51 (-1.05)

Jim Cramer's 'Mad Money' Recap: What's Hot and Fashionable in Stocks
at The Street - Tue Feb 17, 7:26PM CST
Cyber security stocks are among those every portfolio should have, Cramer says.
LMT: 197.66 (-1.44), UNH: 112.88 (-1.91), SKX: 66.79 (-1.65), NGHC: 18.04 (-0.33), INTC: 33.19 (-0.54), PANW: 140.73 (-2.41), JACK: 96.25 (-1.30), RPTP: 10.86 (+0.09), COST: 149.54 (-1.63), LOW: 73.51 (-1.05), REGN: 422.13 (-6.82), TRV: 105.80 (-1.80), CY: 15.10 (-0.40), MU: 28.50 (-0.78), FEYE: 42.83 (-1.08), ETH: 26.49 (+0.04), BRCM: 44.33 (-0.57), VFC: 74.49 (-1.58), EW: 133.00 (-2.65), COLM: 56.19 (-0.66), SMH: 56.68 (-0.72), FIVE: 29.10 (-0.81), WM: 53.65 (-0.85), PCLN: 1,215.99 (-15.91), HAIN: 61.66 (-1.03), CVS: 101.90 (-1.46), JWN: 80.86 (+0.21), FTNT: 33.60 (-0.64)

Surprise! We Still Need Drugmakers to Develop Revolutionary Hepatitis C Drugs
Todd Campbell, The Motley Fool - Motley Fool - Tue Feb 17, 10:02AM CST
Source: Gilead Sciences. All of the market's chatter surrounding Gilead Sciences '  and AbbVie 's hepatitis C drugs this past year may have you thinking that these companies have won the decades long battle against this tough-to-treat disease....
VRTX: 126.34 (-0.62), GILD: 101.81 (-1.61), CVS: 101.90 (-1.46), ABBV: 55.64 (-1.22)

CVS Health Raises Concerns about the Potential Impact of New Class of Cholesterol Drugs on the Health Care System
PR Newswire - Tue Feb 17, 8:00AM CST
CVS Health (NYSE: CVS) weighs in on the next chapter in the debate about the impact of expensive drugs on the health care system in a commentary that appears today on the Health Affairs blog. Currently in development, PCSK9 (proprotein convertase subtilisin/kexin 9) enzyme inhibitors could successfully treat millions of Americans with high cholesterol, but at great cost to the health care system. The authors describe the real challenge is not the cost per dose, but the large eligible patient population and the duration of chronic treatment, which could span decades.
CVS: 101.90 (-1.46)

CVS Health To Present At RBC Capital Markets Healthcare Conference
PR Newswire - Mon Feb 16, 11:20AM CST
CVS Health Corporation (NYSE: CVS) today announced that Dave Denton, executive vice president and chief financial officer, will be speaking to investors at the RBC Capital Markets Healthcare Conference on February 25, 2015, at approximately 10:00 a.m. ET.
CVS: 101.90 (-1.46)

Did Rite Aid Corporation Just Ink a Super-Smart Deal?
Todd Campbell, The Motley Fool - Motley Fool - Mon Feb 16, 8:03AM CST
Source: Wiki Commons user Specious. In order to overcome headwinds from slowing sales and sky-high debt, Rite Aid has been closing stores and sweet-talking lenders for years. The pharmacy operator's recently announced acquisition of...
ESRX: 82.27 (-2.01), WBA: 82.35 (-0.85), CVS: 101.90 (-1.46), RAD: 7.65 (-0.03)

What Can 2014 Results Tell Us About The Future For CVS Health?
David Schauber, Jr. - at Seeking Alpha - Mon Feb 16, 2:09AM CST

CVS: 101.90 (-1.46)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sequel Advisors Rebrand: Founder-Centric M&A Focus

Updated Category News Views 5

What's in a Name? A Shift to Reflect Reality When a company decides it's time to shake things up with a rebrand, they better have a good reason. Enter what's now called Sequel Advisors—shedding the old label, Transact Capital, to let founders know exactly what they’re dealing with upfront. This isn't just some slick, new logo on a letterhead. It's about aligning their...

Continue Reading
VERTESS Tops Axial's 2026 Healthcare M&A Advisor List

Updated Category News Views 5

Strength Takes Top Spot in Healthcare M&A VERTESS has grabbed the gold medal in healthcare sell-side M&A, something that didn't just fall from the sky. Axial gave them the nod as the cream of the crop among the Top 50 Lower Middle Market Healthcare M&A Advisors for 2026. Evaluating the Strengths that Set VERTESS Apart When Axial, that private deal network that's all about...

Continue Reading
NORD Honors Innovators Shaping Rare Disease Treatment

Updated Category News Views 5

Saluting the Trailblazers in Rare Disease Space Alright, let's cut to it. In a world flooded with more rare diseases than most of us can count, about 10,000 of them, only a measly 5% have any kind of approved treatment. The National Organization for Rare Disorders (NORD) is out here celebrating the folks who dare to change that bleak outlook. With the 2026 Rare Impact...

Continue Reading
Spotlight on AI-Powered Smart Homes for 2027

Updated Category News Views 6

Gearing Up for the Connected Home Revolution Ah, the thrill of peering into the future of smart homes! That's what's cookin' as Parks Associates gears up for its annual CONNECTIONS™ Conference slated for May 4-6, 2027. This isn't just another routine pow-wow. Nope, this get-together is about seeing who's leading the pack in transforming our everyday spaces into...

Continue Reading
Unicycive's Legal Turmoil: Opportunity for Investor Action

Updated Category News Views 2

Unicycive's Legal Headache: What's Brewing? Here we go again, folks. If you're holding shares of Unicycive Therapeutics, Inc. (UNCY), buckle up because it's looking like a storm's on the horizon. The Law Offices of Howard G. Smith have dropped the news that shareholders can step up to lead a securities fraud class action lawsuit against the company. That chance to be part...

Continue Reading
Wrensilva Unveils Studio Console in White Oak

Updated Category News Views 4

The White Oak Revolution Out of San Diego, Wrensilva's giving audiophiles a new reason to tune in: the Studio record console now comes dressed to impress in White Oak. This marks a fresh chapter in their craftsmanship tale, marrying sleek design with the earthy charm of this beloved hardwood. And guess what? The demand for serene home listening setups is peaking like...

Continue Reading
BeyondCPG Accelerator Launches Seventh Growth Program

Updated Category News Views 4

Fresh Faces in Conscious Consumerism There's nothing quite like an early morning jolt of caffeine mixed with the buzz of innovation in the air. BeyondCPG, a heavyweight in the conscious products arena, has cracked open the doors to its seventh round of powerhouse brand-boosting with the launch of its new Accelerator Track 7. They're mixing heart with hustle to give...

Continue Reading
CATL Opens Europe's Largest Battery Service Hub

Updated Category News Views 2

A New Era for EV Batteries in Norway Stepping into Oslo's tech realm, CATL's grand opening is not just another corporate ribbon-cutting spree. It's a big splash in Europe's battery pool, boasting the largest NING SERVICE center outside of Asia. Here we are, folks, at the crossroads where the EV market meets the nitty-gritty of practical service. Norway's Electric...

Continue Reading
Alex Jones Returns to Austin: New Studio, New Plans

Updated Category News Views 6

Back in the Saddle: Austin's Controversy Stirs Again It looks like we're seeing a new chapter in a saga that just refuses to end. Alex Jones, the infamous firebrand who's plastered conspiracy theories across the airwaves for two decades, is returning to ground zero in Austin—the old InfoWars studio. After wading through bankruptcy muck and courtroom clashes, Jones is...

Continue Reading
Quantum Sky's Strategic Leadership Overhaul Targets Growth

Updated Category News Views 5

Executive Shake-Up Aims for Stronger Federal Market Alignment Buckle up, folks—there's some major chess-piecing happening at Quantum Sky. They've just named not one or two, but three executive bigwigs to head up their core business groups. This isn’t just some ceremonial reshuffle. Nah, it’s bigger. They're redefining how they tackle the Department of War, Intel &...

Continue Reading

Top 5 Most Recently Viewed Articles

Scale Computing and Acumera Unite to Advance Edge Innovation

Updated Category News Views 295

Scale Computing and Acumera Combine Forces The new company that emerges from the merger will be known simply as Scale Computing. This partnership marks a significant step in the edge computing landscape, offering robust solutions for enterprises seeking to streamline operations across distributed environments. Enhanced Capabilities for a Diverse Clientele With the...

Continue Reading
Analyzing The Mosaic Co's Short Interest Dynamics

Updated Category News Views 195

Understanding The Mosaic Co's Short Interest The Mosaic Co (NYSE: MOS) has recently seen a 4.96% decrease in its short interest as a percentage of float compared to its last report. Currently, there are around 12.81 million shares sold short, which represents 4.6% of the total shares available for trading. Based on the current trading volume, it would take approximately...

Continue Reading
Quay Sunglasses Surge in Popularity Among Trendsetters

Updated Category News Views 7

You know, sunglasses might look like a simple fashion statement, but in 2026, they've morphed into a viral sensation, with Quay leading the pack. It's not just about shielding your eyes from the sun anymore; it's more like throwing on the latest buzzworthy accessory that everyone and their mother is showing off on TikTok. Quay’s Secret Sauce: Visibility and Variety Quay...

Continue Reading
Novartis Pioneers New Direct-to-Patient Platform for Cosentyx

Updated Category News Views 669

Novartis Unveils Direct-to-Patient Platform for Cosentyx In an exciting development for patients in the United States, Novartis has announced the launch of a direct-to-patient (DTP) platform for their leading product, Cosentyx (secukinumab). This initiative aims to improve access and affordability for patients prescribed Cosentyx, allowing cash-paying individuals to...

Continue Reading
Revolutionary Woodworking Auction Sets New Industry Standard

Updated Category News Views 75

A Groundbreaking Woodworking Auction Announcement In a remarkable collaboration, Holland Industrial Group and Machinery Max are thrilled to unveil what is set to be the largest woodworking auction event in recent history. This four-day auction aims to showcase a vast range of state-of-the-art cabinet production and finishing equipment, designed for manufacturers,...

Continue Reading